Stocks / NASDAQ / Medgenics, Inc.

Medgenics, Inc.

Our Opinion

Aevi Genomic Medicine, Inc. formerly known as Medgenics Inc., is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“Our drug product candidates, including NFC-1, must be approved by the FDA through the New Drug Application (“NDA”) process, and future product candidates, including TARGT, may be subject to the Biologic License Application process (“BLA”), before they may be legally marketed in the United States. The process required by the FDA before a drug may be marketed in the United States generally involves Completion of extensive non-clinical, sometimes referred to as non-clinical laboratory tests, non-clinical animal studies ” (Page 8) Read the following document

Company Description

Aevi Genomic Medicine, Inc. formerly known as Medgenics Inc., is a medical technology company, which focuses on finding treatments for rare and orphan diseases, with a particular focus on pediatrics, following a genomics medicine strategy. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. [Source: MarketWatch]

Company Website: